89bio, Inc. (ETNB) Dividend History

Company News

• Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

  The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

  GlobeNewswire Inc.

  Featured Companies: ARWR BBIO CRNX IONS NBIX
• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  89bio, a clinical-stage biopharmaceutical company, announced the grant of non-qualified stock options to four new employees as an inducement to join the company.

  GlobeNewswire Inc.
• 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

  89bio, Inc., a clinical-stage biopharmaceutical company, announced the pricing of its upsized public offering of common stock and pre-funded warrants, raising approximately $125.0 million in gross proceeds.

  GlobeNewswire Inc.
• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on June 10, 2024 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

  GlobeNewswire Inc.
• 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

  -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-

  GlobeNewswire Inc.